Seres Therapeutics
215 First Street
Cambridge
Massachusetts
02142
United States
Tel: 617-945-9626
Website: http://serestherapeutics.com/
Email: info@sereshealth.com
270 articles about Seres Therapeutics
-
Seres Therapeutics and Nestlé Health Science have announced a decision to team up for the joint commercialization of Seres’s investigational oral microbiome treatment for recurrent Clostridioides difficile infections.
-
Flagship Pioneering announced a massive cash infusion to support the development and launch of new companies aiming at various diseases and global health threats.
-
Seres Therapeutics to Present at JMP Securities Life Sciences Conference
6/10/2021
Seres Therapeutics, Inc. today announced that Terri Young, Ph.D., R.Ph., Chief Commercial and Strategy Officer of Seres Therapeutics, will present at the JMP Securities Life Sciences Conference on Thursday, June 17, 2021 at 1:00 p.m. ET.
-
Seres Therapeutics to Host Virtual Investor Event on June 21, 2021
6/10/2021
Seres Therapeutics, Inc. announced that it will host a virtual investor event focused on SER-287 and SER-301, potential new therapeutic options for ulcerative colitis on Monday, June 21, 2021 from 8:30 a.m. to 10:00 a.m. ET.
-
With an oral presentation and a poster at the ASCO Annual Meeting this year, Seres Therapeutics sought to bolster the case for two of its microbiome therapeutics programs.
-
Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD)
6/1/2021
– SER-155 aims to prevent mortality in immunocompromised patients due to gastrointestinal infections, bacteremia and GvHD – – In collaboration with Memorial Sloan Kettering Cancer Center, Seres will now advance SER-155 into a Phase 1b clinical study –
-
Seres Therapeutics to Present at Upcoming Virtual Investor Conferences - May 25, 2021
5/25/2021
Seres Therapeutics, Inc., a leading microbiome therapeutics company, announced that management will present a corporate overview at two upcoming investor conferences
-
Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at Digestive Disease Week 2021
5/21/2021
Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at Digestive Disease Week 2021
-
Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development
5/20/2021
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that David Arkowitz will join as Executive Vice President, Chief Financial Officer (CFO) and Head of Business Development, effective June 1, 2021. Mr. Arkowitz will report directly to Eric Shaff, President and Chief Executive Officer of Seres.
-
Seres Therapeutics to Present Clinical Research on the Microbiome’s Impact on Allogeneic Hematopoietic Stem Cell Transplantation and Cancer Immunotherapy at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
5/19/2021
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it will present the latest research from its early stage clinical development programs in two presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting,
-
Seres Therapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference
5/12/2021
Seres Therapeutics, Inc. , (Nasdaq: MCRB), today announced that management will participate in a panel discussion at the RBC Capital Markets 2021 Global Healthcare Conference on Tuesday, May 18 at 4:15 p.m. ET.
-
Seres Therapeutics to Present Key Data on Investigational Microbiome Therapeutics for Recurrent C. difficile Infection and Ulcerative Colitis at the Digestive Disease Week (DDW) Annual Meeting
5/11/2021
Seres Therapeutics to Present Key Data on Investigational Microbiome Therapeutics for Recurrent C. difficile Infection and Ulcerative Colitis at the Digestive Disease Week (DDW) Annual Meeting - Data demonstrates Seres’ leadership in microbiome sciences and therapeutics across multiple diseases -
-
Seres Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
5/4/2021
– Topline clinical data from SER-287 Phase 2b study in patients with mild-to-moderate ulcerative colitis expected in mid-2021, microbiome biomarker data anticipated in H2 2021 – – Ongoing enrollment in SER-109 open label study for recurrent C. difficile infection; On track to achieve 300 subject enrollment target in Q3 2021 –
-
Seres Therapeutics to Host First Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2021
4/28/2021
Seres Therapeutics, Inc . (Nasdaq: MCRB) a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 4, 2021 at 8:30 a.m. ET to discuss first quarter 2021 results and provide a general business update.
-
Seres Therapeutics to Present at Jefferies Microbiome-Based Therapeutics Summit
4/15/2021
Seres Therapeutics, Inc . (Nasdaq: MCRB) a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will present at the Jefferies Microbiome-Based Therapeutics Summit being held on Thursday, April 22, 2021.
-
Seres Therapeutics to Present at the 31st Annual Oppenheimer Healthcare Conference
3/12/2021
Seres Therapeutics to Present at the 31 st Annual Oppenheimer Healthcare Conference
-
Seres Therapeutics Announces Discontinuation of Enrollment in SER-401 Study in Metastatic Melanoma
3/8/2021
Seres Therapeutics Announces Discontinuation of Enrollment in SER-401 Study in Metastatic Melanoma - Enrollment meaningfully impacted by COVID-19 - - The Company reiterates opportunity in oncology and continues advancement of its preclinical efforts -
-
Microbiome company Seres Therapeutics announced the discontinuation of its Phase Ib trial of SER-401, an orally delivered consortia of bacteria that was intended to boost the efficacy of checkpoint inhibitors in patients with metastatic melanoma.
-
Seres Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Updates
3/2/2021
– SER-287 Phase 2b study in patients with mild-to-moderate ulcerative colitis has achieved target enrollment; topline data expected in mid-2021 – – Continued enrollment in SER-109 open label study in recurrent C. difficile infection to support planned BLA filing; potential to be first FDA-approved microbiome therapeutic – – Conference call at 8:30 a.m. ET today –
-
Seres Therapeutics Announces Achievement of Target Enrollment in SER-287 Phase 2b ECO-RESET Study for Ulcerative Colitis
3/2/2021
- Topline clinical data expected in mid-2021 - - Results will inform Seres’ broader development efforts in UC and other programs targeting modulation of host inflammation and immunity -